Too Good to Be True? Five Top Lessons of Major GLP-1 Agonists Trials
Presenter:
We Recommend
Disclosures
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
- Grant Support/Research Contract - Angel Medical; Bayer AG; Bristol-Myers Squibb; CSL Behring; Janssen; Johnson & Johnson; Portola; SCAD Alliance
- Consultant Fee/Honoraria/Speaker's Bureau - Amarin; Amgen; Angel Medical; Bayer AG; Boehringer Ingelheim; Boston Clinical Research Institute; Boston Scientific Corporation; Caladrius Biosciences; CRF; CeleCor Therapeutics; CSL Behring; Chiesi; DCRI; Eli Lilly and Company; GE Healthcare; Gilead; Impact Bio; Janssen; Johnson and Johnson; The Medicine's Company; MedImmune; Medtelligence; Merck & Co.; Microport; Novo Nordisk; PERT Consortium; Pharma Mar; Portola; Thrombolytic Science; Somahlution; Vereseon; WebMD; Amag Pharmacuticals; Eidos Therapeutics; Kiniksa Pharmaceuticals; Micodrop, LLC
- Equity/Stock(s)/Options - nference
- Royalty/Intellectual Property Rights - UpToDate